Published in J Microsc on August 01, 2010
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother (1983) 8.82
Campylobacter enteritis associated with consumption of unpasteurised milk. Br Med J (1979) 8.45
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis (1980) 8.40
Kidney transplantation under FK 506. JAMA (1990) 7.45
A selective medium for isolating Campylobacter jejuni/coli. J Clin Pathol (1982) 5.59
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother (1978) 4.74
LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 4.52
Antimicrobial resistance. Is a major threat to public health. BMJ (1998) 4.18
Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) (1986) 4.16
The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother (1984) 4.15
Functional anatomy of a common semantic system for words and pictures. Nature (1996) 4.14
Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother (1980) 4.07
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother (1978) 3.68
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.58
Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49
The anatomy of phonological and semantic processing in normal subjects. Brain (1992) 3.41
Rapid diagnosis of Campylobacter-associated gastritis. Lancet (1985) 3.38
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Techniques and interpretations in the serological diagnosis of brucellosis in man. J Med Microbiol (1968) 3.14
The laboratory diagnosis of chronic brucellosis. Lancet (1966) 3.01
Association of Helicobacter pylori infection with coronary heart disease. Study shows association between H pylori infection and hypertension. BMJ (1996) 3.00
Mupirocin resistance. Lancet (1991) 2.88
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother (1985) 2.85
Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother (1984) 2.83
Medical complications after stroke: a multicenter study. Stroke (2000) 2.81
Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother (1984) 2.79
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci (2001) 2.68
Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 2.64
Local surveillance of antimicrobial resistance. Synercid Resistance Surveillance Group. Lancet (1998) 2.60
In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrob Agents Chemother (1978) 2.58
Reward circuitry activation by noxious thermal stimuli. Neuron (2001) 2.56
Comparison of selective media for isolation of Campylobacter jejuni/coli. J Clin Pathol (1983) 2.52
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother (1980) 2.51
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother (1995) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother (1981) 2.48
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites. Antimicrob Agents Chemother (1986) 2.45
Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. J Antimicrob Chemother (1998) 2.42
MRI in schistosomiasis of conus medullaris and lumbar spinal cord. Lancet (1993) 2.40
Maternal feeding practices and beliefs and their relationships to overweight in early childhood. J Dev Behav Pediatr (2001) 2.39
Mycobacterium chelonei isolation from broncho-alveolar lavage fluid and its practical implications. J Hosp Infect (1990) 2.37
A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother (1997) 2.37
A milk-borne outbreak of food poisoning due to Salmonella paratyphi B. var. Java. Public Health (1967) 2.35
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother (1980) 2.35
Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J (1990) 2.33
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res (2000) 2.29
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Functional magnetic resonance imaging of human brain activation during cue-induced cocaine craving. Am J Psychiatry (1998) 2.26
Prokaryotic metabolic activity and community structure in Antarctic continental shelf sediments. Appl Environ Microbiol (2003) 2.23
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res (2001) 2.22
Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum (1999) 2.22
Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J (2002) 2.19
Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J (2009) 2.18
Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology (1999) 2.15
The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother (1984) 2.15
Cardiovascular risk assessment of South Asians in a religious setting: a feasibility study. Int J Clin Pract (2011) 2.12
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother (1982) 2.12
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
Early and late weight gain following smoking cessation in the Lung Health Study. Am J Epidemiol (1998) 2.10
Effective use of comprehensive pediatric care. Utilization of health resources. Am J Dis Child (1968) 2.10
In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother (1990) 2.09
Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs. Antimicrob Agents Chemother (1978) 2.07
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother (1986) 2.04
Reduction in radiation exposure during coronary angiography. Cathet Cardiovasc Diagn (1990) 2.03
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother (1984) 2.01
Prophylactic use of cephazolin against wound sepsis after cholecystectomy. Br Med J (1977) 1.97
Reproducibility of random amplified polymorphic DNA (RAPD) analysis among laboratories. PCR Methods Appl (1993) 1.97
Clinical and laboratory investigations on ticarcillin, an anti-pseudomonal antibiotic. Chemotherapy (1974) 1.97
Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. Antimicrob Agents Chemother (1987) 1.96
Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet (1995) 1.96
BCL-6 expression during B-cell activation. Blood (1996) 1.95
Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis. Eur J Clin Microbiol (1987) 1.93
Rapid diagnosis of Campylobacter pyloridis gastritis. Lancet (1986) 1.92
The cortical localization of the lexicons. Positron emission tomography evidence. Brain (1992) 1.91
Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob Agents Chemother (1980) 1.87
The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother (1986) 1.86
Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J Antimicrob Chemother (1991) 1.85
Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother (1988) 1.85
Use of antibiotics. Penicillins. Br Med J (1978) 1.85
The pharmacokinetics of LY127935, a broad spectrum oxa-beta-lactam. J Antimicrob Chemother (1980) 1.85
Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother (1992) 1.84
Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother (2001) 1.84
Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother (1992) 1.80
Ceftazidime--a new extended-spectrum cephalosporin. Lancet (1982) 1.79
Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol (1991) 1.77
The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. J Antimicrob Chemother (1989) 1.75
Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrob Agents Chemother (1980) 1.75
Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75